| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
18.37(B) |
| Last
Volume: |
534,229 |
Avg
Vol: |
722,222 |
| 52
Week Range: |
$143.31 - $211.65 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,700 |
98,555 |
124,204 |
268,793 |
| Total Sell Value |
$3,224,546 |
$16,182,261 |
$20,937,886 |
$52,053,725 |
| Total People Sold |
1 |
8 |
9 |
10 |
| Total Sell Transactions |
1 |
13 |
19 |
36 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vincent James L |
Director |
– • – |
2010-06-11 |
4 |
OE |
$7.02 |
$105,300 |
D/D |
15,000 |
25,000 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2010-05-27 |
4 |
A |
$0.00 |
$0 |
I/I |
105,400 |
105,400 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2010-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(105,400) |
0 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2010-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
29,600 |
105,400 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2010-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(29,600) |
147,230 |
|
- |
|
| Novartis Pharma Ag |
10% Owner |
– – • |
2010-04-23 |
4 |
B |
$17.99 |
$993,462 |
I/I |
55,223 |
5,602,898 |
1.5 |
- |
|
| Schimmel Paul |
Director |
– • – |
2009-09-10 |
4 |
S |
$22.26 |
$347,289 |
D/D |
(15,600) |
159,088 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2009-09-09 |
4 |
S |
$22.10 |
$662,931 |
D/D |
(30,000) |
174,688 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2009-09-04 |
4 |
S |
$22.02 |
$647,482 |
D/D |
(29,400) |
204,688 |
|
- |
|
| Maraganore John |
CEO |
• • – |
2009-06-18 |
4 |
AS |
$21.37 |
$854,648 |
D/D |
(40,000) |
0 |
|
- |
|
| Maraganore John |
CEO |
• • – |
2009-06-18 |
4 |
OE |
$0.48 |
$19,000 |
D/D |
40,000 |
28,200 |
|
- |
|
| Maraganore John |
CEO |
• • – |
2009-06-17 |
4 |
AS |
$21.40 |
$855,840 |
D/D |
(40,000) |
0 |
|
- |
|
| Maraganore John |
CEO |
• • – |
2009-06-17 |
4 |
OE |
$0.48 |
$19,000 |
D/D |
40,000 |
40,000 |
|
- |
|
| Maraganore John |
CEO |
• • – |
2009-06-16 |
4 |
AS |
$21.43 |
$857,590 |
D/D |
(40,000) |
0 |
|
- |
|
| Maraganore John |
CEO |
• • – |
2009-06-16 |
4 |
OE |
$0.48 |
$19,000 |
D/D |
40,000 |
400 |
|
- |
|
| Novartis Pharma Ag |
10% Owner |
– – • |
2009-05-06 |
4 |
B |
$17.50 |
$1,153,635 |
I/I |
65,922 |
5,547,675 |
1.5 |
- |
|
| Allen Patricia L |
VP of Finance/Treasurer |
• – – |
2009-04-22 |
4 |
AS |
$17.63 |
$440,745 |
D/D |
(25,000) |
0 |
|
- |
|
| Allen Patricia L |
VP of Finance/Treasurer |
• – – |
2009-04-22 |
4 |
OE |
$0.95 |
$23,750 |
D/D |
25,000 |
25,000 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2009-04-14 |
4 |
A |
$0.00 |
$0 |
I/I |
176,830 |
176,830 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2009-04-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(176,830) |
0 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2009-04-14 |
4 |
D |
$0.00 |
$0 |
D/D |
(176,830) |
75,800 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2009-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
176,830 |
252,630 |
|
- |
|
| Vaishnaw Akshay |
SVP, Clinical ResearchOfficer |
• – – |
2009-03-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
799 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2008-09-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
176,830 |
176,830 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2008-09-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
176,830 |
75,800 |
|
- |
|
748 Records found
|
|
Page 25 of 30 |
|
|
2.76 (1.82%) 
